Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. - Wikidata - awgldk - TriplyDB

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

http://www.wikidata.org/entity/Q36938833

about

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients Darbepoetin for the anaemia of chronic kidney disease Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study.Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.Use of agents stimulating erythropoiesis in digestive diseases Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.Erythropoietic stimulating agents.The safety of switching between therapeutic proteins.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Peginesatide for the treatment of renal disease-induced anemia.Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.Treatment of anemia in chronic kidney disease: known, unknown, and both.Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2014.Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease.Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease.Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients.Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study.Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

P2860

Q24187413-B77E7969-8359-402F-AD7C-7C0D1D9C6C3D Q24194545-C18635EF-61A8-4A29-850A-B0A79DB52182 Q24197780-53052CA5-FA6E-4AE0-B8F8-4551CFA8A353 Q33634884-40A4BB6B-5932-48F4-9110-484EAC6923C9 Q34577650-8C541EF7-DCEB-4D33-B063-4A17DF7C11E1 Q34642348-57F938E9-A41C-4A6D-9F6D-2B0468347EF5 Q35904444-CB2CBF8F-9C14-4E24-A654-D3D8AD7AA580 Q37123211-0639DFF4-593A-4A16-848A-330A90AE7325 Q37298741-F70CC341-2C95-4600-B465-BA6CFED91CB2 Q37368733-7BE74C86-8A16-4E63-944B-127BD70CA6D2 Q37473690-6E0E8810-2E92-4A16-A8F1-253C475476AE Q37501907-78D6E51E-39C4-414E-8AC9-89E05ED2B319 Q37693160-18DF6800-767B-4F43-B501-4CA32C0CB248 Q38030980-AE4EB1CE-0BFF-41E9-A73A-B2F7E84F1A72 Q38075798-77E74F43-09A8-4A68-9600-9E4FC7FB30D4 Q38090725-55AE88D8-8ACD-41F4-A89E-0CFBB905D470 Q38634832-5DA3B644-10E6-404D-811E-94F2D5746882 Q38637669-209AF6D0-A022-4542-BBD6-0444283D6721 Q38711130-9803DFE6-FAAE-422B-B063-1B32DC50C7E9 Q38904887-E3DB7EF1-6300-49DF-979C-BDC3EA5246EA Q40540575-6A10D293-A043-493C-8CDF-F8E67C5872EA Q41862721-E5727C37-11E2-4780-98B4-040333FDCC8F Q41975971-5BC865E0-0B7C-4AD8-AB14-EB849E5A5FDE Q42015241-ABC02CB8-228A-4C12-A14A-AA5528FBF875 Q42130626-5ABEB5AD-29C6-4D19-BDD3-A7714E7D22B6 Q42650628-BB952654-EDA1-4E06-9546-B128A04BDD76 Q43525009-F28EAD61-4E57-4AD5-850A-31D8915E7032 Q45988565-4A9BB04A-B2D8-4995-B861-96B850F3F4E5 Q46865481-A3FB5553-40E3-4AC1-96D8-E811BE0E6F17 Q47118771-5D8D5730-8E31-4994-9558-553C1D21FC3C Q48835259-ABE36420-D63B-4FE0-BB44-15B1FED62152 Q50627188-ACD0C1F8-B52B-4F20-98BC-9CDAA5EE5788

P2860

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

http://www.wikidata.org/entity/Q36938833

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Intravenous C.E.R.A. maintains ...... a randomized phase III study.

@en

type

label

Intravenous C.E.R.A. maintains ...... a randomized phase III study.

@en

prefLabel

Intravenous C.E.R.A. maintains ...... a randomized phase III study.

@en

P1433

Q36938833-EAEC19E3-EF28-4F22-B9C5-DC474FB1378B

P1476

Q36938833-4EE3D71F-331C-4D9D-B6C4-7F27611F7374

P2093

Q36938833-1451852E-E49C-430D-AD8C-CF7E01F91948

Q36938833-4A54732F-FF0E-4CD2-A99F-C95029DA64CB

Q36938833-67E24CB0-AC6C-46F9-93CA-9B99D1F58E4C

Q36938833-689E6A64-84EC-4DE3-A9FC-FD48A9F575C6

Q36938833-762E8881-3422-4476-BE45-A4D37A67368C

Q36938833-9092D8FC-DC9B-4DA9-88D9-B9EAAFFA9071

Q36938833-98192297-239B-419C-A5F6-8DBDE0B89B50

Q36938833-AB3B7ADF-5D24-4B02-A29E-7382126A0C3A

Q36938833-BAD7D7F6-837D-4332-80F0-4DF0C9DC06C6

Q36938833-C20E09B4-3E11-4E31-8C77-8943D9B54713

P2860

Q36938833-07B0613A-D188-4CD9-95CF-2BB05D560530

Q36938833-0AFD856C-56CF-4A10-A41F-747F03D3129E

Q36938833-141692BC-E066-4B01-B672-2C8E886AAE1A

Q36938833-218FE510-489F-4081-A38B-3ECA6EF28A6F

Q36938833-28472CF7-6693-4094-AAA0-4EE935568C6B

Q36938833-299856ED-346F-49C7-9C52-15C9453DF85A

Q36938833-41F573F6-C3A0-4530-85C8-6E08949589AC

Q36938833-4952ED10-1A92-4FA7-9741-47DA1BAD1DE9

Q36938833-8359D0DC-C293-4D2B-86B4-60501C045F02

Q36938833-8510C33E-584B-4D2C-83C2-53D1FA4C1ED9

P304

Q36938833-B1B3CF06-5468-4BB6-89A0-F23496A3ECFA

P31

Q36938833-D7F9D0BA-F437-4A7D-BADB-0C7F871A4960

P356

Q36938833-234E50D4-4488-4D41-A62E-51885F8FB897

P407

Q36938833-2850A28C-C150-4649-9248-8DD3E36C343A

P433

Q36938833-8CA4D407-ABD7-4E22-8374-DBDCDE8E4BD5

P478

Q36938833-F75A7A34-AFF9-483A-B9B9-51399CC65104

P50

Q36938833-CBCAB255-98DA-400B-AD25-9608AB428044

P577

Q36938833-46E416B6-B30D-413C-9838-469228546271

P5875

Q36938833-5C343D9C-F5D2-492D-AB7D-E2946572E3F8

P698

Q36938833-0536C3BF-F0D3-4E2C-A44C-7839919EC9BC

P921

Q36938833-1ECB3AC9-5CDF-4602-911C-5CAAF3438708

Q36938833-CAD03566-1423-4315-AAAD-747AB0D678AB

P932

Q36938833-772BBF02-1E30-4BA9-B3CA-6EF3B2871166

P356

P1433

Nephrology Dialysis Transplantation

P1476

Intravenous C.E.R.A. maintains ...... , a randomized phase III study

@en

P2093

Alan W McMahon

http://www.w3.org/2001/XMLSchema#string

Bernard Canaud

http://www.w3.org/2001/XMLSchema#string

Bruno Van Vlem

http://www.w3.org/2001/XMLSchema#string

Cécile Kerloëguen

http://www.w3.org/2001/XMLSchema#string

Francesco Locatelli

http://www.w3.org/2001/XMLSchema#string

Giulio Mingardi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Villa

http://www.w3.org/2001/XMLSchema#string

Johann Braun

http://www.w3.org/2001/XMLSchema#string

Pedro Aljama

http://www.w3.org/2001/XMLSchema#string

Peter G Kerr

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Outcomes of anaemia management in renal insufficiency and cardiac disease.

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay.

Anemia and health-related quality of life in adolescents with chronic kidney disease.

Simulation model of renal replacement therapy: predicting future demand in England.

Forecast of the number of patients with end-stage renal disease in the United States to the year 2010.

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.

DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States.

P304

3654-3661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFN320

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5268747

http://www.w3.org/2001/XMLSchema#string

P698

18586762

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

P932

2568005

http://www.w3.org/2001/XMLSchema#string